October 23, 2023 06:59 AM EDT
Deals
China
Pharma

Mer­ck ax­es two of nine AD­Cs in pact with Kelun-Biotech

Kyle LaHucik

Senior Reporter

Mer­ck has cho­sen not to pick up two pre­clin­i­cal an­ti­body-drug con­ju­gates from its part­ner Sichuan Kelun-Biotech, the Chi­nese drug­mak­er dis­closed Mon­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times